Hybrid Light-Matter Particles Could Transform AI Computing Energy Use
Breaking the Photonic Computing Bottleneck
Researchers at the University of Pennsylvania led by physicist Bo Zhen demonstrated all-optical signal switching using exciton-polaritons on May 18. The advance targets a longstanding hurdle in photonic AI: nonlinear activation steps require converting light signals back into slower, more energy-hungry electronic ones — a translation that erodes the speed and efficiency advantages of optical computing.
4 Femtojoules Per Switching Event
The team confined light inside a nanoscale optical cavity and coupled it with an atomically thin material to create exciton-polaritons — hybrid particles that combine light's propagation speed with matter's capacity to interact strongly. Energy consumed per switching operation: approximately 4 femtojoules (4 × 10⁻¹⁵ J), a dramatic reduction compared with conventional electronics.
A Path to Energy-Efficient AI Hardware
As global AI power demand strains energy infrastructure, photonic computing has long been viewed as a potential successor to electronics-based GPU accelerators. This work removes one of the last practical obstacles to fully optical AI inference — where signals remain as light from input to output — a goal that could slash data center energy consumption by orders of magnitude if scaled to production hardware.
Related Articles
Google-backed UC San Diego researchers plan to build a low-carbon cloud platform from 2,000 retired Pixel phones. The design strips devices to motherboards, groups 25-50 phones into Kubernetes-managed clusters, and targets teaching, grading, and research workloads.
Google Research is framing dermatology AI around user understanding, not just condition labels. A JAMA Dermatology study with 2,345 participants tested whether an AI-powered informational tool helped people identify skin concerns and choose better next steps.
The deal is worth up to about $600M, with roughly $60M in initiation fees, near-term payments, and milestones. Insilico will use Pharma.AI for early discovery while Takeda takes selected candidates into clinical validation and global development.